Precigen Inc (PGEN)

$4.14 +0.09 (2.22%)
Market Cap 1.19B
Revenue (ttm) 3.93M
Net Income (ttm) -126.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,212.21%
Debt to Equity Ratio 0.00
Volume 6,397,000
Avg Vol 6,825,658
Day's Range N/A - N/A
Shares Out 297.97M
Stochastic %K 30%
Beta 1.61
Analysts Strong Sell
Price Target $8.25

Company Profile

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine an...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 556 9900
Address:
20374 Seneca Meadows Parkway, Germantown, United States
Bordeaux17
Bordeaux17 Oct. 31 at 7:59 PM
$PGEN Yeah, this week stung a bit, but zoom out a month and tell me again how this is extremely bearish. Must be that new reverse-psychology trading strategy.
1 · Reply
InvestorWisdom
InvestorWisdom Oct. 31 at 7:51 PM
$PGEN Looks like it wants to push off the 10/21/50DMA. They’re all tight.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 31 at 10:22 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PGEN Current Share Price: $4.05 Contracts: $PGEN January 15, 2027 $4 Calls Scale in: $1.46- $1.79 Scale out: $2.27-$2.93 Can Easily Capture: 60% ROI Blended DTE: 441 Days | Join Elites here: https://liquidtheta.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 30 at 11:42 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PGEN Current Share Price: $4.03 Contracts: $PGEN January 15, 2027 $4 Calls Scale in: $1.57- $1.93 Scale out: $2.45-$3.15 Can Easily Capture: 60% ROI Blended DTE: 442 Days | Join Elites here: https://liquidtheta.com
0 · Reply
Wacousta
Wacousta Oct. 30 at 5:20 PM
$PGEN FYI https://investors.precigen.com/node/14591/html
5 · Reply
1ightningscalps
1ightningscalps Oct. 30 at 5:53 AM
1ightning® Options Trade Alert (Actionable) | Buy $PGEN Nov 21 $4 Call | Enter: $0.40 Exit: $0.61 | Profit: 53.15% ROI | https://1ightning.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 29 at 11:28 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PGEN Current Share Price: $3.99 Contracts: $PGEN January 15, 2027 $4 Calls Scale in: $1.44- $1.76 Scale out: $2.24-$2.88 Can Easily Capture: 60% ROI Blended DTE: 443 Days | Join Elites here: https://liquidtheta.com
0 · Reply
RayD73
RayD73 Oct. 29 at 6:57 PM
$SHORT.X covered 5 mill shares at beginning of this month, pressure is building as information forthcoming on commercial launch
0 · Reply
dsup
dsup Oct. 29 at 4:09 PM
$PGEN insane low volume today….
1 · Reply
Dragonfly41
Dragonfly41 Oct. 29 at 4:05 PM
$PGEN CAPR
0 · Reply
Latest News on PGEN
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

Oct 13, 2025, 7:00 AM EDT - 18 days ago

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

Precigen Announces Up to $125 Million Non-Dilutive Financing

Sep 3, 2025, 7:00 AM EDT - 2 months ago

Precigen Announces Up to $125 Million Non-Dilutive Financing

Precigen, Inc. - Special Call

Sep 2, 2025, 1:55 PM EDT - 2 months ago

Precigen, Inc. - Special Call

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

Aug 25, 2025, 8:05 AM EDT - 2 months ago

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

Undercovered Dozen: Precigen, ONEOK, Bitmine And More

Aug 22, 2025, 10:43 AM EDT - 2 months ago

Undercovered Dozen: Precigen, ONEOK, Bitmine And More

BMNR OKE

Precigen: This Billion-Dollar Approval Is Still Undervalued

Aug 15, 2025, 3:15 PM EDT - 2 months ago

Precigen: This Billion-Dollar Approval Is Still Undervalued

Why Is Precigen Stock Surging On Friday?

Aug 15, 2025, 9:48 AM EDT - 2 months ago

Why Is Precigen Stock Surging On Friday?

US FDA approves Precigen's immunotherapy for rare respiratory disease

Aug 15, 2025, 7:18 AM EDT - 2 months ago

US FDA approves Precigen's immunotherapy for rare respiratory disease

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Aug 15, 2025, 7:00 AM EDT - 2 months ago

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen: August Is Pivotal For This Biotech Innovator

Jul 7, 2025, 5:58 PM EDT - 4 months ago

Precigen: August Is Pivotal For This Biotech Innovator

Precigen Reports First Quarter 2025 Financial Results and Business Updates

May 14, 2025, 4:05 PM EDT - 6 months ago

Precigen Reports First Quarter 2025 Financial Results and Business Updates

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

Apr 16, 2025, 8:05 AM EDT - 7 months ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 7:47 PM EDT - 8 months ago

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

Precigen Reports Full Year 2024 Financial Results and Business Updates

Mar 19, 2025, 4:05 PM EDT - 8 months ago

Precigen Reports Full Year 2024 Financial Results and Business Updates

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

Mar 13, 2025, 8:05 AM EDT - 8 months ago

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

Feb 28, 2025, 8:56 AM EST - 8 months ago

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Feb 25, 2025, 8:05 AM EST - 8 months ago

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 7:00 AM EST - 10 months ago

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:30 AM EST - 10 months ago

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Dec 30, 2024, 7:00 AM EST - 10 months ago

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Dec 27, 2024, 9:00 AM EST - 11 months ago

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Nov 14, 2024, 4:30 PM EST - 1 year ago

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Precigen to Participate in the Stifel 2024 Healthcare Conference

Nov 12, 2024, 4:05 PM EST - 1 year ago

Precigen to Participate in the Stifel 2024 Healthcare Conference

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Sep 16, 2024, 4:30 PM EDT - 1 year ago

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session

Aug 15, 2024, 8:11 AM EDT - 1 year ago

Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session

GGR TITN

Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 7:03 PM EDT - 1 year ago

Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Aug 7, 2024, 9:30 PM EDT - 1 year ago

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Precigen Announces Proposed $30 Million Public Offering of Common Stock

Aug 6, 2024, 4:04 PM EDT - 1 year ago

Precigen Announces Proposed $30 Million Public Offering of Common Stock

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

Jul 23, 2024, 8:01 AM EDT - 1 year ago

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

Jun 3, 2024, 9:30 AM EDT - 1 year ago

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

May 23, 2024, 5:00 PM EDT - 1 year ago

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

Precigen Reports First Quarter 2024 Financial Results and Business Updates

May 14, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports First Quarter 2024 Financial Results and Business Updates

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

May 8, 2024, 4:05 PM EDT - 1 year ago

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Apr 24, 2024, 10:20 AM EDT - 1 year ago

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Actym Therapeutics Appoints Thomas Smart as CEO

Apr 24, 2024, 9:00 AM EDT - 1 year ago

Actym Therapeutics Appoints Thomas Smart as CEO

ANAB XOMA

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 8:49 PM EDT - 1 year ago

Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript

Precigen Reports Full Year 2023 Financial Results and Business Updates

Mar 19, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports Full Year 2023 Financial Results and Business Updates

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Mar 12, 2024, 4:05 PM EDT - 1 year ago

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

Mar 5, 2024, 4:05 PM EST - 1 year ago

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 4:05 PM EST - 1 year ago

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Precigen: RRP Targeting With AdenoVerse Technology Platform

Jan 19, 2024, 7:39 PM EST - 1 year ago

Precigen: RRP Targeting With AdenoVerse Technology Platform

Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Jan 16, 2024, 8:05 AM EST - 1 year ago

Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 8, 2024, 8:30 AM EST - 1 year ago

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 18, 2023, 4:05 PM EST - 2 years ago

Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Precigen to Participate in the JMP Securities Hematology and Oncology Summit

Nov 29, 2023, 4:05 PM EST - 2 years ago

Precigen to Participate in the JMP Securities Hematology and Oncology Summit

Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs

Nov 9, 2023, 4:55 PM EST - 2 years ago

Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs

Bordeaux17
Bordeaux17 Oct. 31 at 7:59 PM
$PGEN Yeah, this week stung a bit, but zoom out a month and tell me again how this is extremely bearish. Must be that new reverse-psychology trading strategy.
1 · Reply
InvestorWisdom
InvestorWisdom Oct. 31 at 7:51 PM
$PGEN Looks like it wants to push off the 10/21/50DMA. They’re all tight.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 31 at 10:22 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PGEN Current Share Price: $4.05 Contracts: $PGEN January 15, 2027 $4 Calls Scale in: $1.46- $1.79 Scale out: $2.27-$2.93 Can Easily Capture: 60% ROI Blended DTE: 441 Days | Join Elites here: https://liquidtheta.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 30 at 11:42 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PGEN Current Share Price: $4.03 Contracts: $PGEN January 15, 2027 $4 Calls Scale in: $1.57- $1.93 Scale out: $2.45-$3.15 Can Easily Capture: 60% ROI Blended DTE: 442 Days | Join Elites here: https://liquidtheta.com
0 · Reply
Wacousta
Wacousta Oct. 30 at 5:20 PM
$PGEN FYI https://investors.precigen.com/node/14591/html
5 · Reply
1ightningscalps
1ightningscalps Oct. 30 at 5:53 AM
1ightning® Options Trade Alert (Actionable) | Buy $PGEN Nov 21 $4 Call | Enter: $0.40 Exit: $0.61 | Profit: 53.15% ROI | https://1ightning.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 29 at 11:28 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PGEN Current Share Price: $3.99 Contracts: $PGEN January 15, 2027 $4 Calls Scale in: $1.44- $1.76 Scale out: $2.24-$2.88 Can Easily Capture: 60% ROI Blended DTE: 443 Days | Join Elites here: https://liquidtheta.com
0 · Reply
RayD73
RayD73 Oct. 29 at 6:57 PM
$SHORT.X covered 5 mill shares at beginning of this month, pressure is building as information forthcoming on commercial launch
0 · Reply
dsup
dsup Oct. 29 at 4:09 PM
$PGEN insane low volume today….
1 · Reply
Dragonfly41
Dragonfly41 Oct. 29 at 4:05 PM
$PGEN CAPR
0 · Reply
1ightningscalps
1ightningscalps Oct. 29 at 8:34 AM
1ightning® Options Trade Alert (Actionable) | Buy $PGEN Nov 21 $4 Call | Enter: $0.48 Exit: $0.77 | Profit: 59.29% ROI | https://1ightning.com
0 · Reply
wallstbullinfinity
wallstbullinfinity Oct. 28 at 5:45 PM
$PGEN $MRNA 2 Companies that are all institutional hype... Watch how horrible they'll continue to perform. It's a new day... Big brotha institutions out, we the people in.
2 · Reply
GSD78626
GSD78626 Oct. 28 at 3:35 PM
$PGEN 🤮
0 · Reply
1ightningscalps
1ightningscalps Oct. 28 at 2:52 AM
1ightning® Options Trade Alert (Actionable) | Buy $PGEN Nov 21 $4 Call | Enter: $0.44 Exit: $0.56 | Profit: 27.04% ROI | https://1ightning.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 27 at 11:33 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PGEN Current Share Price: $4.36 Contracts: $PGEN January 15, 2027 $4 Calls Scale in: $1.57- $1.93 Scale out: $2.45-$3.15 Can Easily Capture: 60% ROI Blended DTE: 445 Days | Join Elites here: https://liquidtheta.com
0 · Reply
Bordeaux17
Bordeaux17 Oct. 27 at 6:19 PM
$PGEN Starting to see a spike in chatter on the RRP support forums around Papzimeos. Dr. Smart’s webinar is now being shared and sparking a lot of discussion, mainly around efficacy and rollout timing. A few patients have already been lined up to receive treatment within the next six months. There’s also talk about when it might become available in Europe. Only real pushback so far is on the pricing — plenty of people unhappy with the cost, but overall awareness and anticipation are clearly ramping up.
3 · Reply
Deivittt
Deivittt Oct. 27 at 10:02 AM
$PGEN Novartis has announced the acquisition of Avidity for approximately $12 billion, integrating these programs into its neuromuscular portfolio. But the drugs remain experimental and have not yet been approved by the FDA. Furthermore, they are for patients with rare genetic diseases. So, what could $PGEN Precigen be worth with a billion-dollar drug approved, the rest of its pipeline, and its innovative and powerful platform?
1 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 26 at 4:35 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PGEN Current Share Price: $4.33 Contracts: $PGEN January 15, 2027 $4 Calls Scale in: $1.50- $1.83 Scale out: $2.33-$2.99 Can Easily Capture: 60% ROI Blended DTE: 446 Days | Join Elites here: https://liquidtheta.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 25 at 6:53 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PGEN Current Share Price: $4.33 Contracts: $PGEN January 15, 2027 $4 Calls Scale in: $1.50- $1.83 Scale out: $2.33-$2.99 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
M22
M22 Oct. 24 at 11:00 PM
$PGEN I like the stock 💎🤲🏻
0 · Reply
Cat651
Cat651 Oct. 24 at 6:31 PM
$PGEN 6’6$ if copy & paste last relative uptrend that ended in 11$
1 · Reply
DenesSzabo
DenesSzabo Oct. 24 at 2:54 PM
$PGEN bought it @3,47 (15 of Oct) and would like to see 4,88 where I close half of the position. (Without Trump this ride has been much easier:))
0 · Reply